Bruton's tyrosine kinase (BTK) inhibitors
Ibrutinib
The FDA lists this product in 18 strengths and forms.
Composition
- Active ingredients
- IBRUTINIB 560MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- IBRUTINIB 140MG · CapsuleANDA211350-001 · Tentative approval
- IBRUTINIB 420MG · TabletANDA212763-003 · Tentative approval
- IBRUTINIB 140MG · TabletANDA212763-001 · Tentative approval
- IBRUTINIB 560MG · TabletThis page
- IBRUTINIB 280MG · TabletANDA212763-002 · Tentative approval
- IBRUTINIB 140MG · CapsuleANDA211344-002 · Discontinued
- IBRUTINIB 70MG · CapsuleANDA211344-001 · Discontinued
- IBRUTINIB 280MG · TabletANDA214296-002 · Tentative approval
- IBRUTINIB 420MG · TabletANDA214296-003 · Tentative approval
- IBRUTINIB 140MG · TabletANDA214296-001 · Tentative approval
- IBRUTINIB 560MG · TabletANDA214296-004 · Tentative approval
- IBRUTINIB 70MG · CapsuleANDA214498-001 · Tentative approval
- IBRUTINIB 140MG · CapsuleANDA214498-002 · Tentative approval
- IBRUTINIB 140MG · Capsule
At a glance
- Brand name
- Ibrutinib
- Drug class
- Bruton's tyrosine kinase (BTK) inhibitors
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Alvogen Pine Brook
- Status
- Tentative approval
- FDA approval
- 9 Apr 2021
- Application
- ANDA212763-004
- RxCUI
- 1442981